Abstract | OBJECTIVE: To carry out an exploratory evaluation of liver triglyceride content in HIV-1-infected patients receiving highly active antiretroviral therapy ( HAART) using proton magnetic resonance spectroscopy and to study how both the treatment itself and the biochemical and physiological variables in which the treatment causes alterations are related to liver fat content. METHODS: Intracellular hepatic triglyceride content was determined in 29 HIV-1-infected patients on their first HAART regime by means of localized water-unsuppressed single voxel proton spectra. Other measurements were body mass index, waist-to-hip ratio, lipodystrophy assessment and a detailed blood biochemical analysis. The relationship between intracellular hepatic triglycerides and relevant descriptive, treatment and biochemical variables was studied by correlation and regression analysis. RESULTS: CONCLUSIONS: The study showed that intrahepatic triglyceride deposit appears to be a frequent feature of HIV-1-infected patients receiving HAART. A coherent multifactorial combination of biochemical and physiological factors associated with the deposit suggested that cumulative exposure to PIs might be a possible trigger event.
|
Authors | Angel Moreno-Torres, Pere Domingo, Jesus Pujol, Francisco Blanco-Vaca, Juan Antonio Arroyo, M Antonia Sambeat |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 12
Issue 2
Pg. 195-203
( 2007)
ISSN: 1359-6535 [Print] England |
PMID | 17503662
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Retroviral Agents
- HIV Protease Inhibitors
- Reverse Transcriptase Inhibitors
- Triglycerides
- Tritium
|
Topics |
- Adult
- Anti-Retroviral Agents
(adverse effects, therapeutic use)
- Antiretroviral Therapy, Highly Active
- Cohort Studies
- Cross-Sectional Studies
- Fatty Liver
(chemically induced, etiology, metabolism, virology)
- Female
- HIV Infections
(complications, drug therapy, metabolism, virology)
- HIV Protease Inhibitors
(therapeutic use)
- HIV-1
- HIV-Associated Lipodystrophy Syndrome
(etiology, metabolism)
- Humans
- Liver
(drug effects, metabolism)
- Magnetic Resonance Spectroscopy
- Male
- Metabolic Syndrome
(complications, metabolism)
- Middle Aged
- Reverse Transcriptase Inhibitors
(therapeutic use)
- Treatment Outcome
- Triglycerides
(metabolism)
- Tritium
|